Overview
Our Approach
Community Involvement
Overview
Sheila Mikhail
Jennifer Anderson
Timothy Ferguson
Fred Johnson
Overview
BioFuels
Clinical Trials
Due Diligence
Entrepreneurial Services
Intellectual Property Management
Joint Ventures and Strategic Alliances
Mergers and Acquisitions
Reduction of Costs
Technology Transfers & Licensing
Venture Capital Financing
Overview
LSL Articles and Presentations
Research Triangle Resources
Entrepreneurial Resources
Life Sciences & Technology Resources
Firm News
Client News
Contact Us
Driving Directions
Recruiting

Client News

 Entegrion, Kedrion form partnership to develop, commercialize Resusix
Feb 18th 2013 - RESEARCH TRIANGLE PARK, N.C. — John B. Mowell, Chairman/Executive Director of Entegrion, announced today the formation of a development and commercialization partnership with Kedrion U.S., a subsidiary of Kedrion Group, SpA, located in Lucca, Italy, for the joint development and worldwide exclusive commercialization rights to Entegrionís dehydrated plasma product Resusix.

The execution of the Collaboration and Exclusive License Agreement, and related agreements for the supply of solvent detergent plasma and technical services during development, formalizes the commitment of Kedrionís technical and distribution capabilities to the Resusix program. Entegrion has retained the rights to separately continue the development of concentrated versions of Resusix. Entegrionís Board and Management believe that the collaboration with Kedrion will support the successful development of Resusix, provide confidence to Entegrionís Government funding sponsors that the program will be successfully executed, and substantially improve Entegrionís financial condition.

"Having Kedrion, a widely recognized worldwide leader in the supply of blood plasma, as both an equity investor and prime supplier for Entegrion results in another milestone in the strategic development of the company," Mowell said. "It further elevates and expands the overall recognition of Entegrion as an integral Ďplayerí in the blood plasma sciences. The Kedrion investment, coupled with the major financial commitment of the Department of Defense for the development of Resusix, is highly indicative of the confidence that is being displayed in Entegrionís research effortsĒ.

Kedrion U.S. is a subsidiary of Kedrion Group, SpA, headquartered in Lucca, Italy, an International leader in the production and distribution of blood plasma-based products, including its pathogen inactivated plasma product that is the input material for Entegrionís Resusix. Entegrion has worked with Kedrion for several years in the preclinical development of Resusix. This collaboration further formalizes Kedrionís participation in the Resusix project, and ensures Kedrionís commitment to supply plasma to Entegrion. In addition to the DoDís need for a long storage life resuscitation product, Kedrion believes Resusix will gain substantial acceptance in the commercial marketplace as an attractive alternative to fresh frozen plasma.

Life Sciences Law, which provides legal counsel to Entegrion, was integral to the success of the deal.

Details 
 Inspiration Parts with OBI-1 rights, Assets in Baxter Deal
Jan 24th 2013 - CAMBRIDGE, Mass. — CAMBRIDGE, Mass. ĖĖ Inspiration Biopharmaceuticals, Inc., in association with global pharmaceutical giant Ipsen (Euronext: IPN; ADR: IPSEY), announced January 24, 2013 the finalization of an Asset Purchase Agreement (APA) deal with Baxter International related to OBI-1, a recombinant porcine (pig) factor VIII drug.
Details 
 MRMC Announces Settlement of Harris County Litigation
Oct 2nd 2012 - KILGORE, Texas — Martin Midstream Partners L.P. (Nasdaq:MMLP) ("MMLP" or the "Partnership") announced October 2, 2012 that Martin Resource Management Corporation (the "Parent"), the owner of its general partner, has settled ongoing litigation with a number of its shareholders.
Read More 
 AskBio, Baxter Announce Partnership to Develop Hemophilia B treatment
Jun 4th 2012 - DEERFIELD, Ill. — Baxter International Inc. (NYSE:BAX) announced today that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chathamís gene therapy technology.
Details 
 InnerOptic Scores Second NIH Grant in Same Number of Months
Jul 6th 2009 - HILLSBOROUGH, N.C. — InnerOptic, a biotechnology company co-founded by Sheila Mikhail, received today its second grant from the National Institutes of Health in two months. The funds will aid the firm's efforts to enhance minimally invasive procedures with its patented visualization technology.
Details 
 InnerOptic Awarded Funding from The National Institutes of Health
Dec 15th 2008 - HILLSBOROUGH, N.C. — Biotech startup InnerOptic Technology, Inc., co-founded by LSL managing member Sheila Mikhail, was awarded today a grant from the National Institutes of Health (NIH) to fund the firmís efforts to fuse CT data with real-time ultrasound imagery
Details 
 ZumaTek Picks Up Research Grant from National Cancer Institute
Oct 23rd 2007 - RESEARCH TRIANGLE PARK, N.C. — ZumaTek, Inc., a breast imaging company co-founded by Sheila Mikhail, earned accolades today from the National Cancer Institute, which awarded the biotech company a Small Business Innovative Research Grant. ZumaTek specializes in the development of cutting-edge, three-dimensional dedicated imaging technologies for enhanced lesion detection.
Details 
 NanoCor Nets $7.5 Million From Biotech Powerhouse Medtronic
Sep 14th 2007 - CHAPEL HILL, N.C. — NanoCor Therapeutics, Inc., which was started and incubated by Life Sciences Law, received today $7.5 million in funding from industry powerhouse, Medtronic, Inc. NanoCor is a biotechnology company focused on developing novel molecular therapies for patients with cardiovascular disease.
Details 

©2013 Life Sciences Law